组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展
[Research Progress of Histone Deacetylase Inhibitor Combined with Immune Checkpoint Inhibitor in the Treatment of Tumor].
作者信息
Fang Chen, Wang Yong, Li Yong
机构信息
Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330000, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):204-211. doi: 10.3779/j.issn.1009-3419.2021.102.11.
Immunotherapy is one of the main strategies of anti-tumor therapy at present, in which immune checkpoint inhibitors (ICIs) are the most widely used drug. ICIs resistance is mediated by a variety of cytokines and immune cells, and the mechanism is complex, which is the main reason for the failure of immunotherapy in cancer patients. Histone deacetylase inhibitor (HDACi), as a class of epigenetic regulatory drugs, plays an important role in regulating cell cycle, proliferation, differentiation, and activity. In recent years, Studies have found that HDACi can not only regulate cell biological characteristics, but also closely related to the improvement of tumor ICIs drug resistance. Therefore, the study on how HDACi enhances the efficacy of ICIs is of great significance to tumor immunotherapy. This article will review the research progress of HDACi combined with ICIs in treating malignant tumors and their related mechanism. .
免疫疗法是目前抗肿瘤治疗的主要策略之一，其中免疫检查点抑制剂（ICIs）是使用最广泛的药物。ICIs耐药性由多种细胞因子和免疫细胞介导，其机制复杂，这是癌症患者免疫治疗失败的主要原因。组蛋白去乙酰化酶抑制剂（HDACi）作为一类表观遗传调控药物，在调节细胞周期、增殖、分化和活性方面发挥着重要作用。近年来，研究发现HDACi不仅可以调节细胞生物学特性，还与肿瘤ICIs耐药性的改善密切相关。因此，研究HDACi如何增强ICIs的疗效对肿瘤免疫治疗具有重要意义。本文将综述HDACi联合ICIs治疗恶性肿瘤的研究进展及其相关机制。
Zotero 插件